Rani V, Aye N, Saksena R, Dabi K, Mannan M, Gaind R
Eur J Clin Microbiol Infect Dis. 2024; 43(4):767-775.
PMID: 38372832
DOI: 10.1007/s10096-024-04784-0.
Bender J, Fleige C, Funk F, Moreto-Castellsague C, Fischer M, Werner G
Antibiotics (Basel). 2024; 13(1).
PMID: 38275330
PMC: 10812394.
DOI: 10.3390/antibiotics13010101.
Yang G, Yan Y, Mao J, Liu H, Chen M, Zhang N
Infect Drug Resist. 2021; 14:5089-5098.
PMID: 34880634
PMC: 8647170.
DOI: 10.2147/IDR.S343200.
Ma X, Zhang F, Bai B, Lin Z, Xu G, Chen Z
Front Public Health. 2021; 9:570650.
PMID: 33614576
PMC: 7893085.
DOI: 10.3389/fpubh.2021.570650.
Krawczyk B, Wysocka M, Kotlowski R, Bronk M, Michalik M, Samet A
PLoS One. 2020; 15(5):e0233504.
PMID: 32453777
PMC: 7250452.
DOI: 10.1371/journal.pone.0233504.
Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus.
Greene M, Harris B, Nesbitt W, Watson M, Wright P, Talbot T
Open Forum Infect Dis. 2018; 5(10):ofy185.
PMID: 30320147
PMC: 6176497.
DOI: 10.1093/ofid/ofy185.
Phenotypic & genotypic characterization of vancomycin resistant Enterococcus isolates from clinical specimens.
Praharaj I, Sujatha S, Parija S
Indian J Med Res. 2014; 138(4):549-56.
PMID: 24434263
PMC: 3868069.
Risk factors associated with linezolid-nonsusceptible enterococcal infections.
McGregor J, Hartung D, Allen G, Taplitz R, Traver R, Tong T
Am J Infect Control. 2012; 40(9):886-7.
PMID: 22361358
PMC: 3644997.
DOI: 10.1016/j.ajic.2011.11.005.
Molecular analysis of linezolid resistance in clinical Enterococcus faecium isolates by polymerase chain reaction and pyrosequencing.
Schnitzler P, Schulz K, Lampson C, Geiss M, Geiss H
Eur J Clin Microbiol Infect Dis. 2010; 30(1):121-5.
PMID: 20814709
DOI: 10.1007/s10096-010-1046-4.
Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.
Scheetz M, Knechtel S, Malczynski M, Postelnick M, Qi C
Antimicrob Agents Chemother. 2008; 52(6):2256-9.
PMID: 18391028
PMC: 2415807.
DOI: 10.1128/AAC.00070-08.
Response to emerging infection leading to outbreak of linezolid-resistant enterococci.
Kainer M, Devasia R, Jones T, Simmons B, Melton K, Chow S
Emerg Infect Dis. 2008; 13(7):1024-30.
PMID: 18214174
PMC: 2878236.
DOI: 10.3201/eid1307.070019.
Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium.
Schulte B, Heininger A, Autenrieth I, Wolz C
Epidemiol Infect. 2007; 136(8):1131-3.
PMID: 17892630
PMC: 2870893.
DOI: 10.1017/S0950268807009508.
Development of Tyrocidine A analogues with improved antibacterial activity.
Marques M, Citron D, Wang C
Bioorg Med Chem. 2007; 15(21):6667-77.
PMID: 17728134
PMC: 2706120.
DOI: 10.1016/j.bmc.2007.08.007.
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
Boak L, Li J, Rayner C, Nation R
Antimicrob Agents Chemother. 2007; 51(4):1287-92.
PMID: 17242144
PMC: 1855482.
DOI: 10.1128/AAC.01194-06.
Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia.
Baddour M, Abuelkheir M, J Fatani A
Ann Clin Microbiol Antimicrob. 2006; 5:30.
PMID: 17140452
PMC: 1713249.
DOI: 10.1186/1476-0711-5-30.
Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.
Bonora M, Solbiati M, Stepan E, Zorzi A, Luzzani A, Catania M
J Clin Microbiol. 2006; 44(3):1153-5.
PMID: 16517918
PMC: 1393143.
DOI: 10.1128/JCM.44.3.1153-1155.2006.
Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis.
Qi C, Zheng X, Obias A, Scheetz M, Malczynski M, Warren J
J Clin Microbiol. 2006; 44(3):1098-100.
PMID: 16517903
PMC: 1393136.
DOI: 10.1128/JCM.44.3.1098-1100.2006.
In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
Draghi D, Sheehan D, Hogan P, Sahm D
Antimicrob Agents Chemother. 2005; 49(12):5024-32.
PMID: 16304168
PMC: 1315934.
DOI: 10.1128/AAC.49.12.5024-5032.2005.
Newer treatment options for skin and soft tissue infections.
Raghavan M, Linden P
Drugs. 2004; 64(15):1621-42.
PMID: 15257625
DOI: 10.2165/00003495-200464150-00002.
Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.
Lobritz M, Hutton-Thomas R, Marshall S, Rice L
Antimicrob Agents Chemother. 2003; 47(10):3318-20.
PMID: 14506047
PMC: 201147.
DOI: 10.1128/AAC.47.10.3318-3320.2003.